Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...

Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.

Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with ...

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...

The common cold is typically caused by viruses, most often rhinoviruses, which infect the upper respiratory tract (nose and throat). 1 Zinc has been reported to block the replication of rhinovirus. By ...

A new study shows that the body’s early immune response, not the virus itself, often determines how severe a rhinovirus cold ...

The technology, called the Viral-Engineered RNA-based Activation System (VERAS), hijacks the virus's own replication machinery to switch on reporter or therapeutic genes precisely in infected cells.

Baculoviruses are a diverse group of insect viruses that have long served as both biological control agents in agriculture and versatile tools in biotechnology. Their life cycle is marked by two ...